nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—BCHE—peripheral nervous system neoplasm	0.415	1	CbGaD
Procainamide—SLC22A3—Melphalan—peripheral nervous system neoplasm	0.186	0.511	CbGbCtD
Procainamide—SLC22A5—Dactinomycin—peripheral nervous system neoplasm	0.0556	0.152	CbGbCtD
Procainamide—SLC22A3—Vincristine—peripheral nervous system neoplasm	0.0551	0.151	CbGbCtD
Procainamide—BCHE—Cisplatin—peripheral nervous system neoplasm	0.0319	0.0876	CbGbCtD
Procainamide—SLC22A2—Cisplatin—peripheral nervous system neoplasm	0.0304	0.0835	CbGbCtD
Procainamide—SCN3A—spinal nerve—peripheral nervous system neoplasm	0.0079	0.197	CbGeAlD
Procainamide—CYP2D6—Doxorubicin—peripheral nervous system neoplasm	0.00512	0.014	CbGbCtD
Procainamide—SCN11A—nerve—peripheral nervous system neoplasm	0.00329	0.0821	CbGeAlD
Procainamide—SCN11A—ganglion—peripheral nervous system neoplasm	0.00325	0.0811	CbGeAlD
Procainamide—SCN8A—nerve—peripheral nervous system neoplasm	0.0025	0.0622	CbGeAlD
Procainamide—DNMT1—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.0018	1	CbGdCrCtD
Procainamide—SCN10A—nerve—peripheral nervous system neoplasm	0.00167	0.0416	CbGeAlD
Procainamide—SCN10A—ganglion—peripheral nervous system neoplasm	0.00165	0.0411	CbGeAlD
Procainamide—SCN11A—trigeminal ganglion—peripheral nervous system neoplasm	0.0016	0.0398	CbGeAlD
Procainamide—SCN7A—trigeminal ganglion—peripheral nervous system neoplasm	0.00136	0.0339	CbGeAlD
Procainamide—SLC22A1—ganglion—peripheral nervous system neoplasm	0.00125	0.0312	CbGeAlD
Procainamide—SLC22A3—tongue—peripheral nervous system neoplasm	0.00118	0.0295	CbGeAlD
Procainamide—SCN8A—brainstem—peripheral nervous system neoplasm	0.00107	0.0267	CbGeAlD
Procainamide—SCN9A—trigeminal ganglion—peripheral nervous system neoplasm	0.00106	0.0265	CbGeAlD
Procainamide—DNMT1—trigeminal ganglion—peripheral nervous system neoplasm	0.00104	0.026	CbGeAlD
Procainamide—DNMT1—parotid gland—peripheral nervous system neoplasm	0.000984	0.0245	CbGeAlD
Procainamide—Sunitinib—CHEK2—peripheral nervous system neoplasm	0.000955	0.168	CrCbGaD
Procainamide—SLC22A2—trigeminal ganglion—peripheral nervous system neoplasm	0.000871	0.0217	CbGeAlD
Procainamide—Sunitinib—ALK—peripheral nervous system neoplasm	0.000851	0.15	CrCbGaD
Procainamide—ACHE—trigeminal ganglion—peripheral nervous system neoplasm	0.000848	0.0211	CbGeAlD
Procainamide—Sunitinib—NTRK1—peripheral nervous system neoplasm	0.000828	0.145	CrCbGaD
Procainamide—SCN10A—trigeminal ganglion—peripheral nervous system neoplasm	0.00081	0.0202	CbGeAlD
Procainamide—SCN1A—brainstem—peripheral nervous system neoplasm	0.00081	0.0202	CbGeAlD
Procainamide—SCN2A—brainstem—peripheral nervous system neoplasm	0.000743	0.0185	CbGeAlD
Procainamide—Oxybuprocaine—BCHE—peripheral nervous system neoplasm	0.00063	0.111	CrCbGaD
Procainamide—SLC22A3—trigeminal ganglion—peripheral nervous system neoplasm	0.000588	0.0147	CbGeAlD
Procainamide—Chloroprocaine—BCHE—peripheral nervous system neoplasm	0.000586	0.103	CrCbGaD
Procainamide—Procaine—BCHE—peripheral nervous system neoplasm	0.000559	0.0982	CrCbGaD
Procainamide—Cinchocaine—BCHE—peripheral nervous system neoplasm	0.000559	0.0982	CrCbGaD
Procainamide—SLC22A3—parotid gland—peripheral nervous system neoplasm	0.000555	0.0138	CbGeAlD
Procainamide—SCN8A—cerebellum—peripheral nervous system neoplasm	0.000528	0.0132	CbGeAlD
Procainamide—DNMT1—cerebellum—peripheral nervous system neoplasm	0.000455	0.0113	CbGeAlD
Procainamide—SLC22A5—trigeminal ganglion—peripheral nervous system neoplasm	0.000428	0.0107	CbGeAlD
Procainamide—BCHE—trigeminal ganglion—peripheral nervous system neoplasm	0.000417	0.0104	CbGeAlD
Procainamide—SLC22A5—parotid gland—peripheral nervous system neoplasm	0.000403	0.0101	CbGeAlD
Procainamide—SCN1A—cerebellum—peripheral nervous system neoplasm	0.000399	0.00995	CbGeAlD
Procainamide—ACHE—cerebellum—peripheral nervous system neoplasm	0.00037	0.00922	CbGeAlD
Procainamide—BCHE—brainstem—peripheral nervous system neoplasm	0.000369	0.00919	CbGeAlD
Procainamide—SCN2A—cerebellum—peripheral nervous system neoplasm	0.000366	0.00914	CbGeAlD
Procainamide—SCN3A—cerebellum—peripheral nervous system neoplasm	0.000322	0.00803	CbGeAlD
Procainamide—Anorexia—Topotecan—peripheral nervous system neoplasm	0.000287	0.00272	CcSEcCtD
Procainamide—Chills—Alitretinoin—peripheral nervous system neoplasm	0.000286	0.00271	CcSEcCtD
Procainamide—Cardiac disorder—Vincristine—peripheral nervous system neoplasm	0.000285	0.0027	CcSEcCtD
Procainamide—Anorexia—Isotretinoin—peripheral nervous system neoplasm	0.000285	0.0027	CcSEcCtD
Procainamide—Anorexia—Tretinoin—peripheral nervous system neoplasm	0.000285	0.0027	CcSEcCtD
Procainamide—SLC22A4—cerebellum—peripheral nervous system neoplasm	0.000282	0.00703	CbGeAlD
Procainamide—Anorexia—Melphalan—peripheral nervous system neoplasm	0.000281	0.00266	CcSEcCtD
Procainamide—Hypotension—Tretinoin—peripheral nervous system neoplasm	0.000279	0.00265	CcSEcCtD
Procainamide—Hypotension—Isotretinoin—peripheral nervous system neoplasm	0.000279	0.00265	CcSEcCtD
Procainamide—Oliguria—Doxorubicin—peripheral nervous system neoplasm	0.000279	0.00264	CcSEcCtD
Procainamide—Ventricular tachycardia—Epirubicin—peripheral nervous system neoplasm	0.000278	0.00263	CcSEcCtD
Procainamide—Ill-defined disorder—Dactinomycin—peripheral nervous system neoplasm	0.000278	0.00263	CcSEcCtD
Procainamide—Bradycardia—Cisplatin—peripheral nervous system neoplasm	0.000277	0.00262	CcSEcCtD
Procainamide—Hypotension—Melphalan—peripheral nervous system neoplasm	0.000276	0.00261	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Topotecan—peripheral nervous system neoplasm	0.000275	0.0026	CcSEcCtD
Procainamide—Renal failure—Etoposide—peripheral nervous system neoplasm	0.000273	0.00258	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Tretinoin—peripheral nervous system neoplasm	0.000272	0.00258	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Isotretinoin—peripheral nervous system neoplasm	0.000272	0.00258	CcSEcCtD
Procainamide—Malaise—Dactinomycin—peripheral nervous system neoplasm	0.00027	0.00256	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.000269	0.00255	CcSEcCtD
Procainamide—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.000262	0.00248	CcSEcCtD
Procainamide—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.00026	0.00246	CcSEcCtD
Procainamide—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.00026	0.00246	CcSEcCtD
Procainamide—Agranulocytosis—Etoposide—peripheral nervous system neoplasm	0.000259	0.00245	CcSEcCtD
Procainamide—Ill-defined disorder—Alitretinoin—peripheral nervous system neoplasm	0.000258	0.00244	CcSEcCtD
Procainamide—Ventricular tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.000257	0.00243	CcSEcCtD
Procainamide—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.000257	0.00243	CcSEcCtD
Procainamide—Myalgia—Dactinomycin—peripheral nervous system neoplasm	0.000255	0.00241	CcSEcCtD
Procainamide—Rash maculo-papular—Epirubicin—peripheral nervous system neoplasm	0.000253	0.00239	CcSEcCtD
Procainamide—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.000252	0.00239	CcSEcCtD
Procainamide—Flushing—Cisplatin—peripheral nervous system neoplasm	0.000252	0.00239	CcSEcCtD
Procainamide—Discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000252	0.00238	CcSEcCtD
Procainamide—Malaise—Alitretinoin—peripheral nervous system neoplasm	0.00025	0.00237	CcSEcCtD
Procainamide—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.000248	0.00235	CcSEcCtD
Procainamide—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.000246	0.00233	CcSEcCtD
Procainamide—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.000246	0.00233	CcSEcCtD
Procainamide—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.000246	0.00233	CcSEcCtD
Procainamide—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.000244	0.00231	CcSEcCtD
Procainamide—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.000244	0.00231	CcSEcCtD
Procainamide—CYP2D6—brainstem—peripheral nervous system neoplasm	0.000244	0.00609	CbGeAlD
Procainamide—Convulsion—Alitretinoin—peripheral nervous system neoplasm	0.000241	0.00228	CcSEcCtD
Procainamide—Urticaria—Topotecan—peripheral nervous system neoplasm	0.000239	0.00227	CcSEcCtD
Procainamide—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.000239	0.00227	CcSEcCtD
Procainamide—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000238	0.00226	CcSEcCtD
Procainamide—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.000238	0.00226	CcSEcCtD
Procainamide—Urticaria—Isotretinoin—peripheral nervous system neoplasm	0.000238	0.00225	CcSEcCtD
Procainamide—Urticaria—Tretinoin—peripheral nervous system neoplasm	0.000238	0.00225	CcSEcCtD
Procainamide—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000236	0.00224	CcSEcCtD
Procainamide—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.000236	0.00224	CcSEcCtD
Procainamide—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.000236	0.00224	CcSEcCtD
Procainamide—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.000236	0.00224	CcSEcCtD
Procainamide—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000236	0.00224	CcSEcCtD
Procainamide—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000236	0.00224	CcSEcCtD
Procainamide—Urticaria—Melphalan—peripheral nervous system neoplasm	0.000234	0.00222	CcSEcCtD
Procainamide—Rash maculo-papular—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.00221	CcSEcCtD
Procainamide—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000234	0.00221	CcSEcCtD
Procainamide—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.000233	0.00221	CcSEcCtD
Procainamide—Convulsion—Vincristine—peripheral nervous system neoplasm	0.000232	0.00219	CcSEcCtD
Procainamide—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000231	0.00219	CcSEcCtD
Procainamide—Flushing—Etoposide—peripheral nervous system neoplasm	0.000231	0.00219	CcSEcCtD
Procainamide—Confusional state—Alitretinoin—peripheral nervous system neoplasm	0.000228	0.00216	CcSEcCtD
Procainamide—Myalgia—Vincristine—peripheral nervous system neoplasm	0.000228	0.00216	CcSEcCtD
Procainamide—Hepatic failure—Epirubicin—peripheral nervous system neoplasm	0.000224	0.00213	CcSEcCtD
Procainamide—Chills—Etoposide—peripheral nervous system neoplasm	0.000223	0.00211	CcSEcCtD
Procainamide—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000223	0.00211	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000223	0.00211	CcSEcCtD
Procainamide—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000222	0.0021	CcSEcCtD
Procainamide—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000222	0.0021	CcSEcCtD
Procainamide—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.00022	0.00209	CcSEcCtD
Procainamide—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.00022	0.00209	CcSEcCtD
Procainamide—Ill-defined disorder—Cisplatin—peripheral nervous system neoplasm	0.000219	0.00208	CcSEcCtD
Procainamide—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000217	0.00206	CcSEcCtD
Procainamide—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000216	0.00205	CcSEcCtD
Procainamide—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000216	0.00204	CcSEcCtD
Procainamide—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000214	0.00203	CcSEcCtD
Procainamide—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000214	0.00203	CcSEcCtD
Procainamide—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000214	0.00202	CcSEcCtD
Procainamide—Malaise—Cisplatin—peripheral nervous system neoplasm	0.000213	0.00202	CcSEcCtD
Procainamide—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000213	0.00202	CcSEcCtD
Procainamide—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000212	0.00201	CcSEcCtD
Procainamide—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.000212	0.00201	CcSEcCtD
Procainamide—Renal impairment—Epirubicin—peripheral nervous system neoplasm	0.000212	0.00201	CcSEcCtD
Procainamide—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000212	0.002	CcSEcCtD
Procainamide—Hypotension—Alitretinoin—peripheral nervous system neoplasm	0.000212	0.002	CcSEcCtD
Procainamide—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000212	0.002	CcSEcCtD
Procainamide—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000212	0.002	CcSEcCtD
Procainamide—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000209	0.00198	CcSEcCtD
Procainamide—Anorexia—Vincristine—peripheral nervous system neoplasm	0.000208	0.00197	CcSEcCtD
Procainamide—Hepatic failure—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.00197	CcSEcCtD
Procainamide—Cardiac failure—Epirubicin—peripheral nervous system neoplasm	0.000207	0.00196	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000206	0.00195	CcSEcCtD
Procainamide—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000206	0.00195	CcSEcCtD
Procainamide—Lethargy—Epirubicin—peripheral nervous system neoplasm	0.000206	0.00195	CcSEcCtD
Procainamide—Convulsion—Cisplatin—peripheral nervous system neoplasm	0.000205	0.00194	CcSEcCtD
Procainamide—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000205	0.00194	CcSEcCtD
Procainamide—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000205	0.00194	CcSEcCtD
Procainamide—Hypotension—Vincristine—peripheral nervous system neoplasm	0.000204	0.00193	CcSEcCtD
Procainamide—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000202	0.00191	CcSEcCtD
Procainamide—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000201	0.00191	CcSEcCtD
Procainamide—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.000201	0.00191	CcSEcCtD
Procainamide—Ill-defined disorder—Etoposide—peripheral nervous system neoplasm	0.000201	0.0019	CcSEcCtD
Procainamide—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.0002	0.00189	CcSEcCtD
Procainamide—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000199	0.00189	CcSEcCtD
Procainamide—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000199	0.00188	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000199	0.00188	CcSEcCtD
Procainamide—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000198	0.00187	CcSEcCtD
Procainamide—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000198	0.00187	CcSEcCtD
Procainamide—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000197	0.00186	CcSEcCtD
Procainamide—Renal impairment—Doxorubicin—peripheral nervous system neoplasm	0.000196	0.00186	CcSEcCtD
Procainamide—Malaise—Etoposide—peripheral nervous system neoplasm	0.000195	0.00185	CcSEcCtD
Procainamide—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.000193	0.00183	CcSEcCtD
Procainamide—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000193	0.00183	CcSEcCtD
Procainamide—Cardiac arrest—Epirubicin—peripheral nervous system neoplasm	0.000192	0.00182	CcSEcCtD
Procainamide—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000192	0.00181	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—peripheral nervous system neoplasm	0.000191	0.00181	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—peripheral nervous system neoplasm	0.00019	0.0018	CcSEcCtD
Procainamide—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00019	0.0018	CcSEcCtD
Procainamide—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00019	0.0018	CcSEcCtD
Procainamide—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.00019	0.0018	CcSEcCtD
Procainamide—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000189	0.00179	CcSEcCtD
Procainamide—Convulsion—Etoposide—peripheral nervous system neoplasm	0.000188	0.00178	CcSEcCtD
Procainamide—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000188	0.00178	CcSEcCtD
Procainamide—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.000187	0.00177	CcSEcCtD
Procainamide—SLC22A5—cerebellum—peripheral nervous system neoplasm	0.000187	0.00465	CbGeAlD
Procainamide—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.000185	0.00175	CcSEcCtD
Procainamide—Abdominal pain upper—Epirubicin—peripheral nervous system neoplasm	0.000184	0.00174	CcSEcCtD
Procainamide—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000184	0.00174	CcSEcCtD
Procainamide—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000182	0.00173	CcSEcCtD
Procainamide—BCHE—cerebellum—peripheral nervous system neoplasm	0.000182	0.00453	CbGeAlD
Procainamide—Hypotension—Cisplatin—peripheral nervous system neoplasm	0.00018	0.00171	CcSEcCtD
Procainamide—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.00018	0.0017	CcSEcCtD
Procainamide—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.00018	0.0017	CcSEcCtD
Procainamide—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000179	0.0017	CcSEcCtD
Procainamide—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000179	0.0017	CcSEcCtD
Procainamide—Nausea—Topotecan—peripheral nervous system neoplasm	0.000179	0.0017	CcSEcCtD
Procainamide—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000179	0.00169	CcSEcCtD
Procainamide—Confusional state—Etoposide—peripheral nervous system neoplasm	0.000178	0.00169	CcSEcCtD
Procainamide—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000178	0.00168	CcSEcCtD
Procainamide—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000178	0.00168	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.00168	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000176	0.00167	CcSEcCtD
Procainamide—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000175	0.00166	CcSEcCtD
Procainamide—Nausea—Melphalan—peripheral nervous system neoplasm	0.000175	0.00166	CcSEcCtD
Procainamide—Benzocaine—ABCB1—peripheral nervous system neoplasm	0.000174	0.0305	CrCbGaD
Procainamide—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000173	0.00164	CcSEcCtD
Procainamide—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.000173	0.00163	CcSEcCtD
Procainamide—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.000173	0.00163	CcSEcCtD
Procainamide—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.000173	0.00163	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.00161	CcSEcCtD
Procainamide—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000169	0.0016	CcSEcCtD
Procainamide—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000168	0.00159	CcSEcCtD
Procainamide—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000167	0.00158	CcSEcCtD
Procainamide—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000167	0.00158	CcSEcCtD
Procainamide—Hypotension—Etoposide—peripheral nervous system neoplasm	0.000165	0.00156	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.000163	0.00154	CcSEcCtD
Procainamide—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000163	0.00154	CcSEcCtD
Procainamide—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000161	0.00152	CcSEcCtD
Procainamide—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.00016	0.00152	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.00151	CcSEcCtD
Procainamide—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000159	0.00151	CcSEcCtD
Procainamide—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000157	0.00148	CcSEcCtD
Procainamide—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000155	0.00147	CcSEcCtD
Procainamide—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000155	0.00147	CcSEcCtD
Procainamide—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000154	0.00146	CcSEcCtD
Procainamide—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000153	0.00145	CcSEcCtD
Procainamide—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000153	0.00145	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.000151	0.00143	CcSEcCtD
Procainamide—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.00015	0.00142	CcSEcCtD
Procainamide—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000149	0.00141	CcSEcCtD
Procainamide—Probenecid—ABCB1—peripheral nervous system neoplasm	0.000148	0.0259	CrCbGaD
Procainamide—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000146	0.00138	CcSEcCtD
Procainamide—Aminohippurate—ABCB1—peripheral nervous system neoplasm	0.000146	0.0256	CrCbGaD
Procainamide—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000145	0.00137	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.000145	0.00137	CcSEcCtD
Procainamide—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000145	0.00137	CcSEcCtD
Procainamide—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000144	0.00137	CcSEcCtD
Procainamide—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000144	0.00136	CcSEcCtD
Procainamide—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000142	0.00135	CcSEcCtD
Procainamide—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000142	0.00135	CcSEcCtD
Procainamide—Lidocaine—ABCB1—peripheral nervous system neoplasm	0.000142	0.0249	CrCbGaD
Procainamide—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.00134	CcSEcCtD
Procainamide—Urticaria—Etoposide—peripheral nervous system neoplasm	0.00014	0.00133	CcSEcCtD
Procainamide—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.00014	0.00132	CcSEcCtD
Procainamide—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00014	0.00132	CcSEcCtD
Procainamide—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000139	0.00131	CcSEcCtD
Procainamide—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000139	0.00131	CcSEcCtD
Procainamide—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000135	0.00127	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000134	0.00127	CcSEcCtD
Procainamide—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000132	0.00125	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000131	0.00124	CcSEcCtD
Procainamide—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.00013	0.00123	CcSEcCtD
Procainamide—Nausea—Vincristine—peripheral nervous system neoplasm	0.00013	0.00123	CcSEcCtD
Procainamide—Flushing—Epirubicin—peripheral nervous system neoplasm	0.00013	0.00123	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.00013	0.00123	CcSEcCtD
Procainamide—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000127	0.0012	CcSEcCtD
Procainamide—Chills—Epirubicin—peripheral nervous system neoplasm	0.000125	0.00119	CcSEcCtD
Procainamide—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000125	0.00118	CcSEcCtD
Procainamide—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000123	0.00116	CcSEcCtD
Procainamide—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000121	0.00115	CcSEcCtD
Procainamide—CYP2D6—cerebellum—peripheral nervous system neoplasm	0.00012	0.003	CbGeAlD
Procainamide—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.00113	CcSEcCtD
Procainamide—Flushing—Doxorubicin—peripheral nervous system neoplasm	0.00012	0.00113	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000119	0.00113	CcSEcCtD
Procainamide—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000117	0.00111	CcSEcCtD
Procainamide—Sunitinib—ABCB1—peripheral nervous system neoplasm	0.000116	0.0204	CrCbGaD
Procainamide—Chills—Doxorubicin—peripheral nervous system neoplasm	0.000116	0.0011	CcSEcCtD
Procainamide—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000115	0.00109	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000113	0.00107	CcSEcCtD
Procainamide—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000112	0.00106	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.00104	CcSEcCtD
Procainamide—Malaise—Epirubicin—peripheral nervous system neoplasm	0.00011	0.00104	CcSEcCtD
Procainamide—Convulsion—Epirubicin—peripheral nervous system neoplasm	0.000105	0.000997	CcSEcCtD
Procainamide—Nausea—Etoposide—peripheral nervous system neoplasm	0.000105	0.000995	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000987	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000979	CcSEcCtD
Procainamide—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000103	0.000979	CcSEcCtD
Procainamide—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000967	CcSEcCtD
Procainamide—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.00096	CcSEcCtD
Procainamide—Confusional state—Epirubicin—peripheral nervous system neoplasm	0.0001	0.000947	CcSEcCtD
Procainamide—Shock—Epirubicin—peripheral nervous system neoplasm	9.75e-05	0.000924	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—peripheral nervous system neoplasm	9.74e-05	0.000922	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	9.71e-05	0.000919	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—peripheral nervous system neoplasm	9.57e-05	0.000906	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	9.57e-05	0.000906	CcSEcCtD
Procainamide—Discomfort—Doxorubicin—peripheral nervous system neoplasm	9.45e-05	0.000895	CcSEcCtD
Procainamide—Anorexia—Epirubicin—peripheral nervous system neoplasm	9.45e-05	0.000895	CcSEcCtD
Procainamide—Hypotension—Epirubicin—peripheral nervous system neoplasm	9.26e-05	0.000877	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—peripheral nervous system neoplasm	9.25e-05	0.000876	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	9.03e-05	0.000855	CcSEcCtD
Procainamide—Shock—Doxorubicin—peripheral nervous system neoplasm	9.02e-05	0.000855	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	8.98e-05	0.00085	CcSEcCtD
Procainamide—Anorexia—Doxorubicin—peripheral nervous system neoplasm	8.74e-05	0.000828	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	8.62e-05	0.000816	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—peripheral nervous system neoplasm	8.57e-05	0.000812	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	8.36e-05	0.000791	CcSEcCtD
Procainamide—SCN5A—Developmental Biology—NCAM1—peripheral nervous system neoplasm	8.33e-05	0.00123	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—PTPN11—peripheral nervous system neoplasm	8.28e-05	0.00123	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—BCHE—peripheral nervous system neoplasm	8.28e-05	0.00123	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—MET—peripheral nervous system neoplasm	8.23e-05	0.00122	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—MET—peripheral nervous system neoplasm	8.23e-05	0.00122	CbGpPWpGaD
Procainamide—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	8.17e-05	0.000774	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	8.11e-05	0.000768	CcSEcCtD
Procainamide—SCN8A—Axon guidance—ERBB2—peripheral nervous system neoplasm	8.09e-05	0.0012	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	8.02e-05	0.00119	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	7.99e-05	0.00118	CbGpPWpGaD
Procainamide—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	7.97e-05	0.000755	CcSEcCtD
Procainamide—SCN10A—Axon guidance—MET—peripheral nervous system neoplasm	7.94e-05	0.00118	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—MET—peripheral nervous system neoplasm	7.94e-05	0.00118	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—PTPN11—peripheral nervous system neoplasm	7.92e-05	0.00117	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—MET—peripheral nervous system neoplasm	7.9e-05	0.00117	CbGpPWpGaD
Procainamide—Urticaria—Epirubicin—peripheral nervous system neoplasm	7.88e-05	0.000746	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	7.84e-05	0.000742	CcSEcCtD
Procainamide—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	7.84e-05	0.000742	CcSEcCtD
Procainamide—CHRM2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	7.63e-05	0.00113	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—PTPN11—peripheral nervous system neoplasm	7.61e-05	0.00113	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—PTPN11—peripheral nervous system neoplasm	7.61e-05	0.00113	CbGpPWpGaD
Procainamide—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	7.56e-05	0.000716	CcSEcCtD
Procainamide—SCN7A—Axon guidance—NRAS—peripheral nervous system neoplasm	7.55e-05	0.00112	CbGpPWpGaD
Procainamide—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	7.5e-05	0.00071	CcSEcCtD
Procainamide—BCHE—Metabolism—PPIP5K2—peripheral nervous system neoplasm	7.44e-05	0.0011	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—PTPN11—peripheral nervous system neoplasm	7.34e-05	0.00109	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—PTPN11—peripheral nervous system neoplasm	7.34e-05	0.00109	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	7.31e-05	0.00108	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	7.31e-05	0.00108	CbGpPWpGaD
Procainamide—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	7.3e-05	0.000692	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—peripheral nervous system neoplasm	7.29e-05	0.00069	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.000687	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	7.25e-05	0.000687	CcSEcCtD
Procainamide—SLC22A3—Metabolism—HSD17B12—peripheral nervous system neoplasm	7.15e-05	0.00106	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	7.15e-05	0.00106	CbGpPWpGaD
Procainamide—CHRM2—Calcium Regulation in the Cardiac Cell—GNAS—peripheral nervous system neoplasm	7.13e-05	0.00106	CbGpPWpGaD
Procainamide—Asthenia—Epirubicin—peripheral nervous system neoplasm	7.11e-05	0.000673	CcSEcCtD
Procainamide—SCN7A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	7.08e-05	0.00105	CbGpPWpGaD
Procainamide—Pruritus—Epirubicin—peripheral nervous system neoplasm	7.01e-05	0.000664	CcSEcCtD
Procainamide—CHRM2—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	6.86e-05	0.00102	CbGpPWpGaD
Procainamide—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	6.78e-05	0.000642	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	6.76e-05	0.00064	CcSEcCtD
Procainamide—SCN11A—Axon guidance—NRAS—peripheral nervous system neoplasm	6.73e-05	0.000997	CbGpPWpGaD
Procainamide—SLC22A2—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	6.66e-05	0.000986	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.64e-05	0.000984	CbGpPWpGaD
Procainamide—SCN5A—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	6.64e-05	0.000984	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—BCHE—peripheral nervous system neoplasm	6.59e-05	0.000977	CbGpPWpGaD
Procainamide—Asthenia—Doxorubicin—peripheral nervous system neoplasm	6.58e-05	0.000623	CcSEcCtD
Procainamide—Dizziness—Epirubicin—peripheral nervous system neoplasm	6.56e-05	0.000621	CcSEcCtD
Procainamide—SCN9A—Axon guidance—ERBB2—peripheral nervous system neoplasm	6.55e-05	0.00097	CbGpPWpGaD
Procainamide—Pruritus—Doxorubicin—peripheral nervous system neoplasm	6.49e-05	0.000615	CcSEcCtD
Procainamide—SLC22A2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	6.39e-05	0.000947	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—MET—peripheral nervous system neoplasm	6.39e-05	0.000947	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	6.31e-05	0.000935	CbGpPWpGaD
Procainamide—Vomiting—Epirubicin—peripheral nervous system neoplasm	6.3e-05	0.000597	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	6.28e-05	0.000594	CcSEcCtD
Procainamide—SCN3A—Axon guidance—ERBB2—peripheral nervous system neoplasm	6.26e-05	0.000927	CbGpPWpGaD
Procainamide—SLC22A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	6.2e-05	0.000919	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	6.19e-05	0.000917	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—NRAS—peripheral nervous system neoplasm	6.16e-05	0.000912	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—BCHE—peripheral nervous system neoplasm	6.15e-05	0.000911	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—MET—peripheral nervous system neoplasm	6.11e-05	0.000905	CbGpPWpGaD
Procainamide—Dizziness—Doxorubicin—peripheral nervous system neoplasm	6.07e-05	0.000574	CcSEcCtD
Procainamide—SCN2A—Axon guidance—ERBB2—peripheral nervous system neoplasm	6.02e-05	0.000891	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—ERBB2—peripheral nervous system neoplasm	6.02e-05	0.000891	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	5.96e-05	0.000883	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.91e-05	0.000875	CbGpPWpGaD
Procainamide—Nausea—Epirubicin—peripheral nervous system neoplasm	5.89e-05	0.000558	CcSEcCtD
Procainamide—SCN2A—Developmental Biology—MET—peripheral nervous system neoplasm	5.87e-05	0.00087	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—MET—peripheral nervous system neoplasm	5.87e-05	0.00087	CbGpPWpGaD
Procainamide—Vomiting—Doxorubicin—peripheral nervous system neoplasm	5.83e-05	0.000552	CcSEcCtD
Procainamide—SCN10A—Axon guidance—ERBB2—peripheral nervous system neoplasm	5.8e-05	0.000859	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—ERBB2—peripheral nervous system neoplasm	5.8e-05	0.000859	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	5.78e-05	0.000856	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	5.75e-05	0.000852	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—MET—peripheral nervous system neoplasm	5.66e-05	0.000839	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—MET—peripheral nervous system neoplasm	5.66e-05	0.000839	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	5.66e-05	0.000839	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.65e-05	0.000837	CbGpPWpGaD
Procainamide—SLC22A4—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	5.65e-05	0.000836	CbGpPWpGaD
Procainamide—ACHE—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.63e-05	0.000834	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MET—peripheral nervous system neoplasm	5.58e-05	0.000826	CbGpPWpGaD
Procainamide—SCN7A—Axon guidance—HRAS—peripheral nervous system neoplasm	5.53e-05	0.000819	CbGpPWpGaD
Procainamide—Nausea—Doxorubicin—peripheral nervous system neoplasm	5.45e-05	0.000516	CcSEcCtD
Procainamide—SCN4A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.43e-05	0.000805	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.43e-05	0.000805	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	5.39e-05	0.000799	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—NRAS—peripheral nervous system neoplasm	5.39e-05	0.000798	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	5.38e-05	0.000796	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.24e-05	0.000776	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	5.24e-05	0.000776	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GNS—peripheral nervous system neoplasm	5.17e-05	0.000766	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—PTPN11—peripheral nervous system neoplasm	5.16e-05	0.000764	CbGpPWpGaD
Procainamide—BCHE—Metabolism—HSD17B12—peripheral nervous system neoplasm	5.02e-05	0.000744	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—NRAS—peripheral nervous system neoplasm	4.98e-05	0.000738	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—NME1—peripheral nervous system neoplasm	4.96e-05	0.000735	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	4.95e-05	0.000733	CbGpPWpGaD
Procainamide—SCN11A—Axon guidance—HRAS—peripheral nervous system neoplasm	4.93e-05	0.00073	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—NRAS—peripheral nervous system neoplasm	4.8e-05	0.000712	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—COX2—peripheral nervous system neoplasm	4.77e-05	0.000707	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—NRAS—peripheral nervous system neoplasm	4.76e-05	0.000706	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	4.72e-05	0.0007	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	4.68e-05	0.000693	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.67e-05	0.000692	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—NRAS—peripheral nervous system neoplasm	4.58e-05	0.000678	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—NRAS—peripheral nervous system neoplasm	4.58e-05	0.000678	CbGpPWpGaD
Procainamide—SCN8A—Axon guidance—HRAS—peripheral nervous system neoplasm	4.5e-05	0.000667	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	4.5e-05	0.000667	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.49e-05	0.000665	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.47e-05	0.000662	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—NRAS—peripheral nervous system neoplasm	4.41e-05	0.000654	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—NRAS—peripheral nervous system neoplasm	4.41e-05	0.000654	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—NRAS—peripheral nervous system neoplasm	4.39e-05	0.000651	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.34e-05	0.000643	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	4.33e-05	0.000641	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	4.31e-05	0.000639	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.29e-05	0.000636	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.29e-05	0.000636	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	4.29e-05	0.000635	CbGpPWpGaD
Procainamide—SLC22A3—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.26e-05	0.000631	CbGpPWpGaD
Procainamide—SLC22A5—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	4.24e-05	0.000629	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	4.18e-05	0.00062	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.14e-05	0.000613	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	4.14e-05	0.000613	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—ERBB2—peripheral nervous system neoplasm	4.08e-05	0.000604	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GNS—peripheral nervous system neoplasm	4.07e-05	0.000603	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—BCHE—peripheral nervous system neoplasm	4.04e-05	0.000599	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MET—peripheral nervous system neoplasm	3.98e-05	0.00059	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.94e-05	0.000584	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	3.92e-05	0.00058	CbGpPWpGaD
Procainamide—ACHE—Metabolism—NME1—peripheral nervous system neoplasm	3.9e-05	0.000578	CbGpPWpGaD
Procainamide—ACHE—Metabolism—COX2—peripheral nervous system neoplasm	3.76e-05	0.000557	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	3.75e-05	0.000556	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—PTPN11—peripheral nervous system neoplasm	3.68e-05	0.000545	CbGpPWpGaD
Procainamide—SCN9A—Axon guidance—HRAS—peripheral nervous system neoplasm	3.64e-05	0.00054	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GNS—peripheral nervous system neoplasm	3.63e-05	0.000538	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.55e-05	0.000526	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.51e-05	0.000521	CbGpPWpGaD
Procainamide—SCN3A—Axon guidance—HRAS—peripheral nervous system neoplasm	3.48e-05	0.000516	CbGpPWpGaD
Procainamide—BCHE—Metabolism—NME1—peripheral nervous system neoplasm	3.48e-05	0.000516	CbGpPWpGaD
Procainamide—SCN7A—Developmental Biology—AKT1—peripheral nervous system neoplasm	3.48e-05	0.000516	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	3.43e-05	0.000508	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	3.43e-05	0.000507	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.42e-05	0.000507	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.4e-05	0.000503	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.38e-05	0.000501	CbGpPWpGaD
Procainamide—BCHE—Metabolism—COX2—peripheral nervous system neoplasm	3.35e-05	0.000497	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	3.35e-05	0.000496	CbGpPWpGaD
Procainamide—SCN2A—Axon guidance—HRAS—peripheral nervous system neoplasm	3.35e-05	0.000496	CbGpPWpGaD
Procainamide—SCN4A—Axon guidance—HRAS—peripheral nervous system neoplasm	3.35e-05	0.000496	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	3.27e-05	0.000484	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.27e-05	0.000484	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.27e-05	0.000484	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GNS—peripheral nervous system neoplasm	3.24e-05	0.000481	CbGpPWpGaD
Procainamide—SCN10A—Axon guidance—HRAS—peripheral nervous system neoplasm	3.23e-05	0.000478	CbGpPWpGaD
Procainamide—SCN1A—Axon guidance—HRAS—peripheral nervous system neoplasm	3.23e-05	0.000478	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—HRAS—peripheral nervous system neoplasm	3.21e-05	0.000476	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	3.15e-05	0.000467	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.15e-05	0.000466	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—NRAS—peripheral nervous system neoplasm	3.15e-05	0.000466	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ENO2—peripheral nervous system neoplasm	3.13e-05	0.000464	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—NME1—peripheral nervous system neoplasm	3.11e-05	0.000461	CbGpPWpGaD
Procainamide—SCN11A—Developmental Biology—AKT1—peripheral nervous system neoplasm	3.1e-05	0.00046	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—NRAS—peripheral nervous system neoplasm	3.1e-05	0.00046	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GNS—peripheral nervous system neoplasm	3.02e-05	0.000448	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	3e-05	0.000444	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—COX2—peripheral nervous system neoplasm	2.99e-05	0.000443	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—NRAS—peripheral nervous system neoplasm	2.98e-05	0.000441	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	2.97e-05	0.00044	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—ERBB2—peripheral nervous system neoplasm	2.91e-05	0.000431	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—NME1—peripheral nervous system neoplasm	2.9e-05	0.000429	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.84e-05	0.00042	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—COX2—peripheral nervous system neoplasm	2.79e-05	0.000413	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	2.75e-05	0.000407	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	2.74e-05	0.000406	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.72e-05	0.000403	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.67e-05	0.000396	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—BCHE—peripheral nervous system neoplasm	2.65e-05	0.000392	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.6e-05	0.000385	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	2.54e-05	0.000376	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.53e-05	0.000375	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—SLC2A1—peripheral nervous system neoplasm	2.53e-05	0.000374	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—TH—peripheral nervous system neoplasm	2.49e-05	0.000369	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	2.49e-05	0.000369	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.49e-05	0.000368	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ENO2—peripheral nervous system neoplasm	2.47e-05	0.000365	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.39e-05	0.000354	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.39e-05	0.000354	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	2.32e-05	0.000344	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NTS—peripheral nervous system neoplasm	2.31e-05	0.000343	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.31e-05	0.000342	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.3e-05	0.000341	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—HRAS—peripheral nervous system neoplasm	2.3e-05	0.000341	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.3e-05	0.00034	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—HRAS—peripheral nervous system neoplasm	2.27e-05	0.000336	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.26e-05	0.000335	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CD55—peripheral nervous system neoplasm	2.22e-05	0.000328	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—NRAS—peripheral nervous system neoplasm	2.21e-05	0.000328	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ENO2—peripheral nervous system neoplasm	2.2e-05	0.000326	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.2e-05	0.000325	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.11e-05	0.000312	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.11e-05	0.000312	CbGpPWpGaD
Procainamide—ACHE—Metabolism—BCHE—peripheral nervous system neoplasm	2.08e-05	0.000309	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.03e-05	0.000301	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—AKT1—peripheral nervous system neoplasm	2.03e-05	0.000301	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—GNAS—peripheral nervous system neoplasm	2.03e-05	0.000301	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	2.02e-05	0.000299	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ABCB1—peripheral nervous system neoplasm	1.99e-05	0.000295	CbGpPWpGaD
Procainamide—ACHE—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.99e-05	0.000295	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ENO2—peripheral nervous system neoplasm	1.97e-05	0.000291	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TH—peripheral nervous system neoplasm	1.96e-05	0.00029	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—MYC—peripheral nervous system neoplasm	1.95e-05	0.000288	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—HRAS—peripheral nervous system neoplasm	1.94e-05	0.000288	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	1.94e-05	0.000287	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	1.88e-05	0.000279	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ENO2—peripheral nervous system neoplasm	1.83e-05	0.000271	CbGpPWpGaD
Procainamide—BCHE—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.77e-05	0.000263	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	1.76e-05	0.000261	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VIP—peripheral nervous system neoplasm	1.75e-05	0.00026	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TH—peripheral nervous system neoplasm	1.75e-05	0.000259	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—HRAS—peripheral nervous system neoplasm	1.73e-05	0.000257	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	1.69e-05	0.000251	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GNS—peripheral nervous system neoplasm	1.67e-05	0.000247	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—BCHE—peripheral nervous system neoplasm	1.66e-05	0.000246	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—HRAS—peripheral nervous system neoplasm	1.62e-05	0.00024	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	1.62e-05	0.00024	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NME1—peripheral nervous system neoplasm	1.6e-05	0.000237	CbGpPWpGaD
Procainamide—ACHE—Metabolism—GNAS—peripheral nervous system neoplasm	1.6e-05	0.000237	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.58e-05	0.000235	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ABCB1—peripheral nervous system neoplasm	1.57e-05	0.000233	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TH—peripheral nervous system neoplasm	1.56e-05	0.000231	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—BCHE—peripheral nervous system neoplasm	1.55e-05	0.000229	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—HRAS—peripheral nervous system neoplasm	1.55e-05	0.000229	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—COX2—peripheral nervous system neoplasm	1.54e-05	0.000228	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	1.54e-05	0.000228	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	1.48e-05	0.000219	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TH—peripheral nervous system neoplasm	1.46e-05	0.000216	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—HRAS—peripheral nervous system neoplasm	1.44e-05	0.000214	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—AKT1—peripheral nervous system neoplasm	1.43e-05	0.000212	CbGpPWpGaD
Procainamide—BCHE—Metabolism—GNAS—peripheral nervous system neoplasm	1.43e-05	0.000211	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ABCB1—peripheral nervous system neoplasm	1.4e-05	0.000207	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—AKT1—peripheral nervous system neoplasm	1.35e-05	0.0002	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—GNAS—peripheral nervous system neoplasm	1.27e-05	0.000189	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ABCB1—peripheral nervous system neoplasm	1.25e-05	0.000185	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	1.21e-05	0.00018	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—GNAS—peripheral nervous system neoplasm	1.19e-05	0.000176	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ABCB1—peripheral nervous system neoplasm	1.17e-05	0.000173	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	1.07e-05	0.000158	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	1.04e-05	0.000154	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ENO2—peripheral nervous system neoplasm	1.01e-05	0.00015	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	9.9e-06	0.000147	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	9.09e-06	0.000135	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—BCHE—peripheral nervous system neoplasm	8.55e-06	0.000127	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.16e-06	0.000121	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TH—peripheral nervous system neoplasm	8.04e-06	0.000119	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—GNAS—peripheral nervous system neoplasm	6.56e-06	9.72e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ABCB1—peripheral nervous system neoplasm	6.44e-06	9.54e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	6.43e-06	9.52e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	6.32e-06	9.36e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—AKT1—peripheral nervous system neoplasm	5.49e-06	8.13e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.99e-06	7.39e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	4.7e-06	6.97e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	4.57e-06	6.77e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	4.53e-06	6.71e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—AKT1—peripheral nervous system neoplasm	4.32e-06	6.4e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	4.15e-06	6.15e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—AKT1—peripheral nervous system neoplasm	3.85e-06	5.71e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.8e-06	5.62e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MYC—peripheral nervous system neoplasm	3.54e-06	5.24e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—AKT1—peripheral nervous system neoplasm	3.44e-06	5.1e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—AKT1—peripheral nervous system neoplasm	3.21e-06	4.75e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.9e-06	4.3e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.78e-06	4.12e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.45e-06	3.63e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—AKT1—peripheral nervous system neoplasm	1.77e-06	2.62e-05	CbGpPWpGaD
